Preprocedural fibrinogen levels and MACE after percutaneous coronary intervention
Journal Title: Archives of Medical Science - Year 2006, Vol 2, Issue 1
Abstract
Introduction: Fibrinogen is a risk factor for cardiovascular disease and is related to the severity of coronary atherosclerosis. According to many studies elevated fibrinogen levels in patients with coronary angioplasty can be useful in predicting target vessel revascularization (TLR) and major adverse cardiac events (MACE). Material and methods: The studied group included 33 patients (10 – female and 23 males; mean age 62.9±8.9 years). The control group consisted of 30 persons (9 – females and 21 maels; mean age 61.8±9.8) who did not develop MACE during 12 months of follow-up. All patients were hospitalized from the beginning of 2003 to March of 2004 for acute coronary syndrome (ACS) and underwent percutaneous coronary intervention (PCI). Preprocedural concentrations of fibrinogen were measured in all patients. The aim of our study was to assess the preprocedural level of fibrinogen in patients developing MACE in comparison to patients from the study group. Results: We have not found statistically significant differences in the level of fibrinogen between the studied groups and the levels of fibrinogen persisted within the normal range of values. Conclusions: The level of fibrinogen within the normal limits can not define the group of patients after ACS who are at a high risk for developing MACE.
Authors and Affiliations
Leszek Markuszewski, Marcin Makowski, Jacek Rysz, Konrad Masiarek, Robert Pietruszyński, Emilia Dobrowolska
Keywords
Related Articles
- EP ID EP91129
- DOI -
- Views 180
- Downloads 0
Clinical and neuropsychological predictors of the diagnosis of dementia with Lewy bodies
Introduction: The pattern of clinical symptoms and cognitive impairment in dementia with Lewy bodies (DLB) is different from Alzheimer’s disease (AD). The aim of this study was to determine which clinical or neuropsychol...
Apolipoproteins C-II and C-III and small dense low density lipoprotein: novel risk factors in metabolic syndrome?<br /> Commentary on: Theodosios D. Filippatos et al. Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome (Arch Med Sci 2008; 4, 3: 263–269)<br />
The role of statins in patients with arterial hypertension
Dear Readers
Medical Education and the Bologna Process